AINOS INC (AIMD)
NASDAQInformation TechnologyBiotechnologySnapshot 2026-11-05
$0.63-14.01%
Close 2026-11-05 · 1-day change
NASDAQInformation TechnologyBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · AIMD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“During the first half of 2026, we continued executing our commercialization roadmap by expanding AI Nose deployments across semiconductor manufacturing, industrial infrastructure, healthcare, and ro…
Stated in 2 of 2 supplied quarters. Management reported: “We continue to believe our activities will help support broader revenue generation opportunities in the second half of 2026.”” “We believe our current execution priorities will help support broader revenue generation opportunities in the second half of 2026,” Mr. Lee added.” Revenue was $0.000 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Information Technology names rated weak grew net income 47% of the time over the next year (vs 59% for the rest of the cohort, n=6380).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““During the first half of 2026, we continued executing our commercialization roadmap by expanding AI Nose deployments across semiconductor manufacturing, industrial infrastructure, healthcare, and ro…”
“During the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments while continuing to expand its Smell ID datasets…”
Mr. Lee continued, “We remain committed to disciplined capital allocation and financial management while supporting our core commercialization strategy, technology development, and deployment priorit…
Stated in 2 of 2 supplied quarters. Management reported: “Mr. Lee continued, “We remain committed to disciplined capital allocation and financial management while supporting our core commercialization strategy, technology development, and deployment priorities.” “Reported operating expenses declined approximately 30% year-over-year to approximately US$2.28 million.”” Operating income was $-4.399 million in 2026-Q2.
“Mr. Lee continued, “We remain committed to disciplined capital allocation and financial management while supporting our core commercialization strategy, technology development, and deployment priorit…”
“Reported operating expenses declined approximately 30% year-over-year to approximately US$2.28 million.””
“Since December 2025, AI Nose has accumulated approximately 613 million industrial smell data records, primarily from semiconductor manufacturing environments.
Stated in 2 of 2 supplied quarters. Management reported: ““Since December 2025, AI Nose has accumulated approximately 613 million industrial smell data records, primarily from semiconductor manufacturing environments.” “During the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments while continuing to expand its Smell ID datasets and refine its Smell Language Model (“SLM”) through deployment and pilot activities.”
““Since December 2025, AI Nose has accumulated approximately 613 million industrial smell data records, primarily from semiconductor manufacturing environments.”
“During the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments while continuing to expand its Smell ID datasets…”
This structure reduces Ainos’ need to independently finance subsequent development, expand specialist teams and devote additional management resources to pharmaceutical execution, supporting the Comp…
Stated in a supplied disclosure. Management reported: “Ainos expects to complete the agreed contractual delivery shortly, with an initial license fee of $600,000 payable within 15 business days after the applicable payment conditions are satisfied.” “This structure reduces Ainos’ need to independently finance subsequent development, expand specialist teams and devote additional management resources to pharmaceutical execution, supporting the Company’s priority investment in Chemical Intelligence.”
Use financing and disciplined financial management to support commercialization and technology development.
Over the trailing year it converted 0.44x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
10 material management or governance events in the past 24 months, led by M&A activity. Historically, Information Technology names rated neutral grew net income 56% of the time over the next year (vs 55% for the rest of the cohort, n=8114).
Not investment advice. As of 2026-11-05.